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Introduction: There is substantial evidence for the onco-
genic effects of ﬁbroblast growth factor receptor 1 (FGFR1)
in many types of cancer, including lung cancer, but the role
of this receptor has not been addressed speciﬁcally in lung
adenocarcinoma.
Methods:We performed FGFR1 and EGFR overexpression
and co-overexpression assays in adenocarcinoma and in
inmortalized lung cell lines, and we also carried out
surrogate and interaction assays. We performed mono-
therapy and combination EGFR/FGFR inhibitor sensitivity
assays in vitro and in vivo in cell line– and patient-
derived xenografts. We determined FGFR1 mRNA
expression in a cohort of patients with anti–EGFR ther-
apy–treated adenocarcinoma.
Results: We have reported a cooperative interaction between
FGFR1 and EGFR in this context, resulting in increased EGFR
activation and oncogenic signaling. We have provided in vitro
and in vivo evidence indicating that FGFR1 expression in-
creases tumorigenicity in cells with high EGFR activation in
EGFR-mutated and EGFR wild-type models. At the clinical
level, we have shown that high FGFR1 expression levels pre-
dict higher resistance to erlotinib or geﬁtinib in a cohort of
patients with tyrosine kinase inhibitor–treated EGFR-mutated
and EGFR wild-type lung adenocarcinoma. Dual EGFR and
FGFR inhibition in FGFR1-overexpressing, EGFR-activated
models shows synergistic effects on tumor growth in vitroand in cell line– and patient-derived xenografts, suggesting
that patients with tumors bearing these characteristics may
beneﬁt from combined EGFR/FGFR inhibition.
Conclusion: These results support the extended the use of
EGFR inhibitors beyond monotherapy in the EGFR-mutated
adenocarcinoma setting in combination with FGFR in-
hibitors for selected patients with increased FGFR1 over-
expression and EGFR activation.Journal of Thoracic Oncology Vol. 14 No. 4: 641-655
642 Quintanal-Villalonga et al Journal of Thoracic Oncology Vol. 14 No. 4 2019 International Association for the Study of Lung Can-
cer. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Lung cancer is the leading cause of cancer-related
deaths, being responsible for 27% of cancer mortality.
Within lung cancer, adenocarcinoma represents the most
prevalent histological type. Several driver alterations
that are responsible for the initiation and progression of
these tumors have been identiﬁed. Of these, one of the
most relevant at the therapeutic level is mutation in the
tyrosine kinase receptor EGFR, which is found in up to
20% of adenocarcinomas in white cohorts and in up to
30% to 50% of patients of Asiatic origin.1,2 The discov-
ery of these alterations and the development of EGFR
inhibitors have signiﬁcantly improved outcomes for such
patients.3 However, in spite of the beneﬁts achieved by
EGFR inhibition, tumor relapse is universal and there are
patients whose tumors harbor unknown EGFR mutations
or exhibit EGFR activation without mutations, thereby
excluding them as candidates for these therapies.4–6 The
identiﬁcation of predictive biomarkers for EGFR therapy
and novel therapeutic approaches with higher efﬁcacy
for treatment of these tumors is therefore crucial.
Besides EGFR, other tyrosine kinase receptors are
currently gaining attention as potential therapeutic tar-
gets. Included among these is the ﬁbroblast growth factor
receptor (FGFR) family, which is involved in the pro-
gression of a variety of cancers.7–11 In lung cancer,
ﬁbroblast growth factor receptor 1 (FGFR1) has shown
oncogenic properties in preclinical models of squamous
cell carcinomas, in which ampliﬁcation of the gene is
frequently observed through the activation of relevant
signaling pathways such as signal transducer and acti-
vator of transcription (STAT), AKT, and mitogen-
activated protein kinase,12–15 opening the door for
potential therapeutic targeting in this histological type of
lung cancer. However, even though the preclinical results
of using FGFR inhibitors were promising, the efﬁcacy of
drugs targeting FGFR1 in clinical trials has so far been
discrete in this tumor subtype.16 For this reason, the
current main patient selection criterion for use of these
inhibitors, namely, ﬁbroblast growth factor receptor 1
gene (FGFR1) ampliﬁcation, which is also seen in 1% to
3% of lung adenocarcinomas,17,18 is being questioned,
and there is in fact evidence showing that FGFR1 mRNA
and FGFR1 protein expression may be better predictors
of FGFR inhibition efﬁcacy.19,20 In light of these results,current research on FGFR inhibition is focused on the
identiﬁcation of optimal predictive biomarkers.21
Furthermore, there may be a cooperative interaction
between EGFR and FGFR1 in lung adenocarcinomas, as
FGFR1 upregulation has been reported as a mechanism of
resistance to EGFR-targeted therapy.22–24 In this work,
we have aimed to study the biological interactions be-
tween both signaling pathways and the potential thera-
peutic implications of their inhibition.
Materials and Methods
Cell Lines
Characteristics of the cell lines used are shown in
Supplementary Table 1. All cell lines were grown in
accordance with the American Type Culture Collection
indications and were authenticated and regularly tested
for Mycoplasma.
Transfections
Cell lines were transfected with TransIT-X2 (Mirus,
Madison, WI). FGFR1 (RC202080) complementary DNA
clones were obtained from Origene (Rockville, MD) in
the pCMV6 plasmid (PS100001). Wild-type EGFR and
EGFR L858R/T790M in the pBABE plasmid, as well as
the empty pBABE plasmid were obtained from Addgene
(Cambridge, MA).
Growth Factor Stimulation
Cells were cultured in fetal bovine serum–free me-
dium for 5 hours to induce basal phosphorylation levels
and then stimulated with serum-free medium containing
ﬁbroblast growth factor 1 (50 ng/mL [Immunostep,
Orsay, France]), epidermal growth factor (EGF) (50
ng/mL [Immunostep]), or complete medium (10% fetal
bovine serum) for 15 minutes. Protein extracts were
subsequently obtained as indicated later in this article.
Surrogated Assays
Surrogated assays were performed as indicated in
Guijarro et al.25 For growth curves, multiple 12-well
plates were seeded with 10,000 cells/well and ﬁxed
every 2 days. Cell proliferation was determined by
crystal violet staining normalized to the day 0 plate. For
clonability and soft agar assays, the number of colonies
was counted after a period of 2 weeks to 1 month after
seeding. A minimum of three biological replicates (in-
dependent experiments) were performed for each assay.
For each biological replicate, three technical replicates
per condition were carried out.
Coimmunolocalization
Anti-EGFR (Thermo Fisher Scientiﬁc, Waltham, MA)
and anti-FGFR1 (Cell Signaling Technology, Danvers, MA)
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Scientiﬁc) and Alexa Fluor 555 secondary antibodies
(Thermo Fisher Scientiﬁc) were used under the conditions
suggested by the manufacturer. Photographs of 15 to 20
cells per condition were taken with an SP5-WLL confocal
microscope (Leica Microsystems, Wetzlar, Germany).
Cell Line Treatments
The concentration required to inhibit cell growth by
50% (GI50) was calculated as in Moneo et al.
26 For
combination treatments, the GI50 values of the EGFR
inhibitors were calculated in the presence of the
approximate mean value of the IC20 FGFR-inhibitor
concentration and the double of this concentration
value. The synergism between both kind of inhibitors
was calculated as by Chou.27 To study treatments’ effects
on downstream signaling, cells were treated for 24 hours
with the erlotinib GI50 alone or in combination with the
GI50 of AZD4547, and protein extraction was performed.
PDXs
We have used a collection of patient-derived xenograft
(PDX)models thatwereconstructedon thebasisofpatients
withNSCLC and established by our group at the Institute of
Biomedicine in Seville. Early-stage resected lung tumors
from patients from Hospital Universitario Virgen del Rocío
in Seville, Spain, were obtained through the hospital bio-
bank and inoculated subcutaneously and expanded in
successive groups of nude mice. For this study, PDXs were
selected depending on their histological type, genetic
background, and FGFR1 expression and EGFR activation.
We have used three models: TP103 (EGFR and p53
mutated), TP57, and TP126 (KRAS and p53 mutated).
Mutational proﬁle was determined by the OncoNIM Seq
Lung Panel, and the speciﬁc mutation frequency was
determined by digital droplet polymerase chain reaction.
The human samples were stored at the Hospital Uni-
versitario Virgen del Rocío Biobank after written informed
consent forms were signed by all patients.
Cell Line and PDXs and In Vivo Treatments
For cell line xenografts, 2  106 cells in phosphate-
buffered saline/Matrigel (1:1) were injected into fe-
male 6-week-old athymic nude mice. For the PDXs,
previously ampliﬁed tumors were cut into 50- to 100-
mm3 pieces, and each was inserted subcutaneously
into one ﬂank of the mouse. Four mice were included in
the control groups and six mice were included in the
experimental groups on the basis of previous work in the
laboratory. Tumors were measured twice a week, and
when tumor volume had reached 150 to 200 mm3, the
mice were randomized into groups with similar mean
tumor sizes and SDs. Mouse weights were measuredonce a week to monitor toxicity. Mice were humanely
killed at the end of treatment and tumors harvested.
Erlotinib, AZD4547, or their combination was adminis-
tered 5 times a week, at a dose of 50 mg of erlotinib/kg/
d for the erlotinib-resistant models and a dose of 25 mg
erlotinib/kg/d for the erlotinib-sensitive models.
AZD4547 was administered at a concentration of 5 mg/
kg/d. The same therapeutic schedule was used for the
osimertinib treatments but with a dose of 10 mg/kg/d.
All drugs were administered by oral gavage. The dura-
tion of the treatments was 5 weeks unless rapid tumor
growth necessitated an earlier end point. In these ex-
periments, blinding was achieved by having one person
treat the animals and a different person measure the
tumors and processing the data.
Immunoblot
Western blot was performed as indicated by Ferrer
et al.28 with use of the following antibodies: FGFR1 (Cell
Signaling Technology), pFGFR1 (Millipore, Bedford, MA),
AKT (Cell Signaling Technology), phosphorylated AKT
(pAKT) (Cell Signaling Technology), p42/p44 (Cell
Signaling Technology), p-p42/p44 (Cell Signaling Tech-
nology), signal transducer and activator of transcription 3
(STAT3) (Cell Signaling Technology), phosphorylated
STAT3 (pSTAT3) (Cell Signaling Technology), a-tubulin
(Sigma, St. Louis, MO), b-actin (Sigma), EGFR (Cell
Signaling Technology), and phosphorylated EGFR (pEGFR)
(Cell Signaling Technology). Western blot images with a
high number of lanes were assembled from blots run in
parallel and with a common reference sample on both gels.
Coimmunoprecipitation
Coimmunoprecipitation was performed by using the
EZ View Red Protein G Afﬁnity Gel (Sigma). Protein ex-
tracts were made in HEPES 50 mM, NaCl 150 mM, and n-
octylglucoside 1% and supplemented with a protease
inhibitor cocktail (cOmpleteMini, Roche, Indianapolis,
IN) and a phosphatase inhibitor cocktail (PhosSTOP,
Roche). Next, 2-mg protein aliquots were precleared and
incubated with the antibody-conjugated beads. The
EGFR antibody (Cell Signaling Technology) was used in a
1:100 dilution for the immunoprecipitation, and an equal
amount of anti–immunoglobulin G isotype control anti-
body (Cell Signaling Technology) was used as a negative
control. Immunocomplexes were denatured by boiling in
Laemmli buffer, and a Western blot protocol was per-
formed to conﬁrm the immunoprecipitation and assess
the coimmunoprecipitation of FGFR1.
RNA Extraction and Analysis
RNA extraction of parafﬁn-embedded patient tumor
tissues was performed with the RecoverAll Extraction Kit
Figure 1. Effect of ﬁbroblast growth factor receptor 1 (FGFR1) overexpression on tumorigenesis of EGFR mutation–driven
lung adenocarcinoma cell lines. (A) Characterization of FGFR1 and EGFR protein expression and EGFR activation in a
panel of lung cell lines. (B) Growth curves in 10% fetal bovine serum and (C) clonability assays of FGFR1-overexpressing EGFR-
mutated adenocarcinoma cell lines. (D) Western blotting of the activation of the EGFR and receptor tyrosine kinase–related
signaling pathways in the FGFR1-overexpressing, EGFR-mutated H1975 and HCC827 lung adenocarcinoma cell lines compared
with that in the empty vector (EV)-containing cell lines after stimulation with recombinant human epidermal growth factor.
(E) Western blotting of the activation of the EGFR and receptor tyrosine kinase–related signaling pathways in FGFR1-
overexpressing H1975 and HCC827 cells after stimulation with the ﬁbroblast growth factor receptor–speciﬁc ﬁbroblast
growth factor 1. (F) Growth assessment of the tumors generated by FGFR1-overexpressing H1975 and HCC827 cell lines. Four
and ﬁve mice were included in the EV and FGFR1 groups, respectively. The colony number is shown for the clonability assays.
All the values were normalized to the EV control, and the mean of all the normalized replicates is presented. For Western
blotting, cells were serum-starved for 5 hours before protein extraction. For the growth factor–stimulated conditions, serum-
starved cells were stimulated with serum-free medium containing FGF1 15 minutes before protein extraction. All experi-
ments were reproduced a minimum of three times in the laboratory. For growth curves and Western blots, a representative
ﬁgure/image is shown. On the growth curves, the means and SDs for the technical replicates are shown. p Values were
644 Quintanal-Villalonga et al Journal of Thoracic Oncology Vol. 14 No. 4
April 2019 FGFR1 Cooperates with EGFR in Lung Cancer 645(Life Technologies, Grand Island, NY). RNA samples were
reverse transcribed with the TaqMan Reverse Transcrip-
tion Kit (Life Technologies). Gene expression was analyzed
after a preampliﬁcation step performed with the TaqMan
Preamp Master Mix Kit (Applied Biosystems, Foster City,
CA) by using two TaqMan probes from Life Technologies:
Hs00917379_m1 FAM (FGFR1) andHs99999907_m1 FAM
(beta-2-microglobulin [B2M]). B2Mexpressionwasused to
normalize the expression data.
Information on sensitivity to EGFR inhibitors lapatinib
and erlotinib and of FGFR1 mRNA expression was ob-
tained from the Cancer Cell Line Encyclopedia database
(https://portals.broadinstitute.org/ccle/home), which is
a public database of cancer cell lines’ sensitivity to EGFR
inhibitors.Clinical Samples
The present study involved a cohort of 87 subjects in
whom advanced (stage IIIC–IV) NSCLC had been diagnosed
at the University Hospital 12 de Octubre (Madrid, Spain)
and who had been given erlotinib or geﬁtinib as their or a
further line of treatment. Tumor samples were sent to a
pathology laboratory for diagnosis andprepared for storage
by formalin ﬁxation and parafﬁn embedding. The inclusion
criteriawere (1) a conﬁrmed diagnosis of NSCLC, (2) access
to patient clinical information, and (3) availability of tumor
tissue obtained by surgical resection. For the tumormarker
prognostic study, the Reporting Recommendations for Tu-
mor Marker Prognostic Study29 reporting guidelines were
followed. Baseline characteristics of the patient cohorts are
summarized in Supplementary Table 2.Study Approval
Written informed consent was provided by all pa-
tients. The project was approved by the research ethics
committee of the Hospital Universitario 12 Octubre
(Madrid, Spain) (CEI 16/297). The procedures involving
animals were approved by the animal protection com-
mittee of the Comunidad Autónoma de Madrid (Approval
ID PROEX134/16).Statistics
In vitro data are represented as the mean plus or
minus SD to indicate variation within each group of data.obtained with the two-sided Mann-Whitney U test and are indica
the H1781 cell line, referred to as EGFR wild-type in the litera
mutation was detected. Because of the high number of cell line
in parallel with common internal reference samples, and the
adenocarcinoma; ALK, ALK receptor tyrosine kinase transloc
mutated; TN, triple negative (referring to the absence of KRAS
pEGFR, phosphorylated EGFR; pFGFR1, phosphorylated ﬁbrobl
activator of transcription 3; pSTAT3, phosphorylated signal tran
AKT.Statistical analysis was performed with the SPSS statis-
tical package (version 19, IBM Corporation, Armonk, NY).
The in vitro and in vivo experiments were analyzed by
using an unpaired nonparametric Mann-Whitney U or
Student t tests. p Values less than 0.05 were considered
signiﬁcant. The Kaplan-Meier method was utilized for
survival analyses of the clinical data and cell line xeno-
graft experiments. Overall survival was deﬁned as the
length of time from the date of starting treatment to the
date of death or last follow-up. Progression-free survival
was deﬁned as the length of time from the date of treat-
ment initiation to the date of progression/death or last
follow-up. A log-rank test was used to analyze differences
in survival among groups. To obtain the hazard ratio (HR)
values, the Cox proportional hazards model was used.
Results
First, wemeasured protein expression levels of FGFR1
and EGFR in adenocarcinoma cell lines with different
genetic backgrounds and in two immortalized epithelial
lung cell lines (see Supplementary Table 1). Relevant
EGFR activation was observed in the EGFR-mutated cell
lines, as expected, and in two other additional cell lines,
Calu3 and H1781, without known EGFR mutations
(Fig. 1A). EGFRmutational proﬁling in these two cell lines
revealed no EGFR activating mutations in either cell line
(data not shown). FGFR1 protein expressionwas detected
in a few of the cell lines tested, but no relevant pFGFR1
was detected by Western blot (data not shown).
FGFR1 Cooperates with EGFR, Enhancing Its
Tumorigenic Properties in Lung Adenocarcinoma
Cell Lines
To study the role of FGFR1 in the context of EGFR-
dependent lung adenocarcinoma, FGFR1 was overex-
pressed in adenocarcinoma cells with different EGFR
mutations. FGFR1 overexpression in these cell lines
(fold changes in FGFR1 expression of 15.2 and 24.7 for
H1975 and HCC827, respectively) increased prolifera-
tion and clonability (Fig. 1B and C) relative to that in the
control cell lines. Only one of these cell lines, HCC827,
was able to form colonies in soft agar in our hands and
produced a higher number of colonies that were also
slightly bigger when FGFR1 was overexpressed
(Supplementary Fig. 1A).ted by asterisks (*p < 0.05, **p < 0.01, and ***p < 0.001). *In
ture (see Supplementary Table 1), the EGFR activating L858R
s analyzed, not ﬁtting in a single gel, different gels were run
assembled images including all cell lines are shown. ADC,
ation; I, immortalized; KRAS, KRAS mutated; EGFR, EGFR
, EGFR, and ALK alterations); FGFR1, FGFR1-overexpressing;
ast growth factor receptor 1; STAT3, signal transducer and
sducer and activator of transcription 3; pAKT, phosphorylated
Figure 2. Oncogenic cooperation of ﬁbroblast growth factor receptor 1 (FGFR1) with mutated and wild-type activated EGFR.
Growth curves in 10% fetal bovine serum (A) for NL20 cell lines overexpressing FGFR1 with or without coexpression of wild-
type or EGFR L858R/T790M. (B) Clonability assays of the entire panel of NL20 cell lines generated. (C) Western blotting of
proteins involved in the activation of ﬁbroblast growth factor receptor–related signaling pathways in the FGFR1-EGFR
interaction models after stimulation with fetal bovine serum in the NL20 cell line panel. For growth curves, a representa-
tive ﬁgure/image is shown. On the growth curves, the mean and SD for the technical replicates are shown. The colony
number is shown for the clonability. All the values were normalized to the empty vector (EV) control, and the mean of all the
normalized replicates is presented. For Western blots, a representative image is shown. p Values were obtained with the two-
sided Mann-Whitney U test and are indicated by asterisks (*p < 0.05, **p < 0.01; and ***p < 0.001). EV1, empty vector 1; EV2,
empty vector 2; F1, FGFR1; EGFRwt, wild type EGFR; EGFRm, mutant EGFR L858R/T790M; pEGFR, phosphorylated EGFR;
pFGFR1, phosphorylated ﬁbroblast growth factor receptor 1; pSTAT3, phosphorylated signal transducer and activator of
transcription 3; STAT3, signal transducer and activator of transcription 3; pAKT, phosphorylated AKT.
646 Quintanal-Villalonga et al Journal of Thoracic Oncology Vol. 14 No. 4We subsequently analyzed the activation of some
signaling pathways related to EGFR and FGFRs in these
cell lines. Under basal conditions, FGFR1 overexpression
increased EGFR activation and slightly increasedFigure 3. Interaction of EGFR with ﬁbroblast growth factor rece
FGFR1 in the NL20 cell lines overexpressing wild-type EGFR and
H1975 cell line. FGFR1 indicates FGFR1 overexpression, and E
pendent images were captured in the immunoﬂuorescence assa
The coimmunoprecipitation assays were independently reprod
protein sample before immunoprecipitation; OUTPUT, protei
phenylindole; IP, immunoprecipitation.STAT3 and AKT signaling in H1975 and HCC827 cells.
After EGF stimulation, pEGFR levels were higher in the
FGFR1-overexpressing cell lines, and p42/p44 activation
was also greater in FGFR1-overexpressing HCC827 cellsptor 1 (FGFR1). (A) Coimmunolocalization assays of EGFR and
FGFR1. (B) Coimmunoprecipitation of EGFR with FGFR1 in the
GFR indicates EGFR overexpression. A minimum of 15 inde-
ys, and representative images for each condition are shown.
uced three times and a representative blot is shown. INPUT,
n sample after immunoprecipitation; DAPI, 40,6-diamino-2-
April 2019 FGFR1 Cooperates with EGFR in Lung Cancer 647than in the empty vector cell line. Interestingly, activa-
tion of the overexpressed FGFR was also increased by
EGF stimulation (Fig. 1D and Supplementary Fig. 1B),
suggesting a cooperation between EGFR and FGFR1.
Complementarily, EGFR activation was promoted in
FGFR1-overexpressing H1975 and HCC827 cells treated
with the FGFR1-speciﬁc growth factor ﬁbroblast growth
factor 1 (Fig. 1E and Supplementary Fig. 1C). These re-
sults suggest that activation of either FGFR1 leads to
increased EGFR signaling.
In addition, we xenografted the FGFR1-
overexpressing H1975 and HCC827 cell lines into
immunodeprived nude mice and monitored tumor
growth. In these xenografts, FGFR1 overexpression
increased tumor growth relative to that in the control
xenografts (Fig. 1F).
The Cooperation between FGFR1 and EGFR Is not
Speciﬁc to Constitutively Activated Forms of
Mutant EGFR
To explore whether the cooperation between FGFR1
and EGFR is dependent on the presence of activating
mutations in EGFR, different EGFR variants were over-
expressed alone or in combination with FGFR1 in the
immortalized epithelial lung cell line NL20 and surrogate
assays were performed. Individual expression of FGFR1
or wild-type EGFR in the NL20 cell line increased pro-
liferation to an extent similar to that the empty vector.
When wild-type EGFR was coexpressed with FGFR1, the
proliferation rate was signiﬁcantly higher than under
any of the previously mentioned conditions. Over-
expression of the EGFR L858R/T790M variant alone
increased proliferation compared with overexpression of
wild-type EGFR. Finally, overexpression of FGFR1 in
combination with EGFR L858R/T790M evoked the
highest proliferation rate of all the cultures (Fig. 2A). In
the clonability assay, increases in colony number were
consistent with the reported effects on proliferation
(Fig. 2B).
In general, overexpression of FGFR1 or wild-type
EGFR increased the activation of the EGFR, STAT3,
AKT, and p42/p44 signaling pathways, and this activa-
tion was further increased when wild-type EGFR was co-
overexpressed with FGFR1. Overexpression of the
constitutively active EGFR L858R/T790M mutant
induced an even greater activation of these signaling
pathways, and this effect was further enhanced by
coexpressing mutant EGFR with FGFR1 (Fig. 2C and
Supplementary Fig. 1D).EGFR Physically Interacts with FGFR1
By immunoﬂuorescence, we found that EGFR
partially colocalized with FGFR1 in the cell membrane inthe FGFR1-overexpressing, EGFR-overexpressing NL20
cell line (Fig. 3A). In addition, coimmunoprecipitation
assays performed on a cell line with endogenous high
levels of pEGFR and detectable FGFR1 expression
(H1975) (see Fig. 1A) showed that FGFR1 coimmuno-
precipitates with EGFR (Fig. 3B).Combined EGFR and FGFR Inhibition Has
Synergistic Effects In Vitro
Because of the aforementioned cooperation between
EGFR and FGFR1, we tested the effects of the combined
EGFR plus FGFR inhibition in the FGFR1-ovexpressing
H1975 and HCC827 cell lines in vitro. We selected two
EGFR inhibitors, erlotinib and osimertinib, and two se-
lective FGFR inhibitors, AZD4547 and BGJ398. FGFR1
overexpression increased sensitivity to FGFR inhibitors
and increased resistance to EGFR inhibitors compared
with in the control cell lines (Fig. 4A). These effects were
speciﬁc to the EGFR-dependent cell lines, as they were
not reproduced in three different adenocarcinoma cell
lines with no EGFR activation (Supplementary Fig. 1E).
Consistently, high FGFR1 expression increased resis-
tance to different EGFR inhibitors in lung adenocarci-
noma and in NSCLC cell lines from a public database
(Cancer Cell Line Encyclopedia) (Supplementary Fig. 2A
and B). Furthermore, combined EGFR and FGFR inhibi-
tion exhibited synergy (Fig. 4B). As erlotinib combined
with AZD4547 showed the strongest synergistic effect,
this combination was chosen for further experiments.
Next, we determined the molecular effects of erloti-
nib and AZD4547 treatment, alone or in combination, in
H1975 and HCC827 cell lines (Fig. 4C). In the FGFR1-
overexpressing cell lines, although partial inhibition of
pEGFR was achieved after erlotinib treatment, further
abrogation of EGFR activation was reported after treat-
ment with the combination of both inhibitors. Similar
results were obtained for p42/p44 activation. Regarding
the AKT signaling pathway, in the FGFR-overexpressing
HCC827 cell line, the combination of both inhibitors
decreased pAKT levels, as compared with when erlotinib
was used alone, whereas no signiﬁcant effects on this
signaling pathway were reported for combination
treatment in the H1975 cell line. Concerning the STAT3
signaling pathway, in the FGFR1-overexpressing H1975
cell line, the combination of both inhibitors showed a
more pronounced reduction of pSTAT3 than with erlo-
tinib monotherapy. Interestingly, in the HCC827 cell line,
erlotinib treatment increased pSTAT3 activation. How-
ever, the addition of AZD4547 to erlotinib treatment of
this cell line reduced this erlotinib-induced STAT3 acti-
vation. When the erlotinib-resistant H1975 cell line was
treated with osimertinib and AZD4547 in monotherapy
and in combination, the combination treatment showed
648 Quintanal-Villalonga et al Journal of Thoracic Oncology Vol. 14 No. 4
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signaling abrogation, as compared with when either
monotherapy was used (Fig. 4D).
Dual Inhibition of EGFR and FGFR Is an Effective
Therapeutic Approach for EGFR-Activated
FGFR1/4-Expressing Tumors
We assessed the efﬁcacy of combined erlotinib/
AZD4547 treatment in vivo in EGFR-mutated xenograft
models (H1975 and HCC827 cells). No toxicity was re-
ported during these treatments (data not shown). In
both models, FGFR1 overexpression resulted in higher
sensitivity to FGFR inhibition, with a greater reduction in
tumor growth after AZD4547 monotherapy than in the
controls. This effect seemed to be FGFR speciﬁc, as FGFR
inhibition did not signiﬁcantly reduce tumor growth in
the controls. Tumors generated by the H1975 cell line
were intrinsically resistant to erlotinib treatment. How-
ever, combination of erlotinib with AZD4547 improved
efﬁcacy, especially in the FGFR1-overexpressing tumors.
In the HCC827 xenografts, FGFR1 overexpression
conferred increased resistance to EGFR inhibition, which
was reversed by the combined treatment (Fig. 5A and B).
In terms of downstream signaling in the H1975 and
HCC827 xenografts, AKT, p42/p44, and STAT3 signaling
was increased in the tumors with FGFR1 overexpression
relative to the increase in the controls, as was found
in vitro. In both models, AZD4547 effectively reduced the
activation of these signaling pathways only in the
FGFR1-overexpressing xenografts. In the H1975 xeno-
graft model, erlotinib caused only a slight decrease in
pAKT and p-p42/p44 levels, which was enhanced by
AZD4547 combination in the FGFR1-overexpressing xe-
nografts. In the HCC827 xenografts, erlotinib treatment
reduced AKT and p42/p44 activation, which was again
further reduced by the combination therapy. As reported
in vitro, erlotinib increased pSTAT3 levels in the HCC827
xenograft models, and only the combined treatmentFigure 4. In vitro effects of ﬁbroblast growth factor receptor 1
receptor (FGFR) inhibitors’ sensitivity. (A) Concentration require
BGJ398 and AZD4547 and EGFR inhibitors erlotinib and osime
overexpression of FGFR1. Nanomolar concentrations for all cell
FGFR-targeted therapies in these cell lines, assessed by the c
concentration of either FGFR inhibitor (1000 or 2000 nM) and a
the GI50 of the different EGFR-FGFR inhibitors combinations. T
combination therapy has an additive effect. Values under this
values showing strong synergism. (C) Effects of the combination
cell lines. (D) Effects of the combination of osimertinib and AZ
H1975 cell line. Cells were treated with the GI50 concentratio
All experiments were reproduced a minimum of three times i
for the technical replicates are shown. Protein extraction was p
and 2 mM of AZD4547. For Western blots, a representative im
Mann-Whitney U test and are indicated by asterisks (*p < 0
FGFR1, FGFR1-overexpressing; pFGFR1, phosphorylated ﬁbrobl
pSTAT3, phosphorylated signal transducer and activator of tra
scription 3; pAKT, phosphorylated AKT.decreased STAT3 activation relative to that in the control
(Fig 5C and Supplementary Fig. 2C).
Finally,we tested the effects of the combined therapy
on three lung adenocarcinoma PDXs. First, we selected a
model harboring EGFR L858R activating and T790M
erlotinib resistance mutations (respective frequencies
31.2% and 17.4%) with high FGFR1 expression (TP103,
Fig. 6A). In this model, erlotinib or AZD4547 mono-
therapy treatments modestly reduced tumor growth
relative to that of the untreated tumors, and combination
therapy showed higher efﬁcacy (Fig. 6B and C). From a
molecular standpoint, p-p42/p44 and pAKT levels were
similarly reduced by erlotinib or AZD4547 monotherapy,
and further reduction in the activation of these signaling
pathways was achieved with combined therapy. In this
model, erlotinib treatment also increased pSTAT3 levels,
as compared with in the untreated control, and only the
combination treatment could effectively reduce STAT3
activation (Fig. 6D).
As our previous in vitro and in vivo observations
indicated that the EGFR-FGFR1 cooperation also takes
place in the context of wild-type activated EGFR, we
decided to test the efﬁcacy of the erlotinib and AZD4547
treatments in two lung wild-type EGFR adenocarcinoma
PDX models with high pEGFR and FGFR1 protein levels
(TP57 and TP126, both KRAS mutated [see Fig. 6A]). In
both models, erlotinib or AZD4547 monotherapy slightly
reduced tumor growth relative to that in the untreated
tumors, but their combination showed much stronger
efﬁcacy (see Fig. 6B and C). In line with these results,
combined therapy inhibited EGFR, FGFR1, STAT3, p42/
p44, and AKT to a greater extent than did either drug
alone (Fig. 6D).
In addition, we tested the efﬁcacy of combined
AZD4547 and osimertinib treatment in the TP103 model,
as osimertinib speciﬁcally targets the T790M EGFR
mutation present in this PDX. This combination was not
toxic (data not shown). Osimertinib treatment(FGFR1) overexpression in EGFR and ﬁbroblast growth factor
d to inhibit cell growth by 50% (GI50) assays of FGFR inhibitors
rtinib in the H1975 and HCC827 cell lines, with or without
lines are shown. (B) Effects of the combination of EGFR- and
ombinatory index (CI). Cell lines were treated with a ﬁxed
range of concentrations of either EGFR inhibitor to calculate
he dashed line indicates the values (around CI ¼ 1) at which
line (CI < 1) reﬂect synergism. The gray area indicates the
of erlotinib and AZD4547 on protumorigenic signaling in these
D4547 on protumorigenic signaling in the erlotinib-resistant
n of either inhibitor for 24 hours before protein extraction.
n the laboratory. In the GI50 assay results, the mean and SD
erformed after a 24-hour treatment with the GI50 of erlotinib
age is shown. p Values were obtained with the two-sided
.05, **p < 0.01, ***p < 0.001). EV, empty vector control;
ast growth factor receptor 1; pEGFR, phosphorylated EGFR;
nscription 3; STAT3, signal transducer and activator of tran-
Figure 5. Effect of dual EGFR and ﬁbroblast growth factor receptor inhibition in xenograft models. (A) Effect of erlotinib
and AZD4547 on tumor growth of two EGFR-mutated adenocarcinoma cell line xenograft models, H1975 and HCC827, with
or without ﬁbroblast growth factor receptor 1 (FGFR1) overexpression. Relative tumor growth is shown, calculated as
tumor volume increase from the beginning of the treatment. (B) Mean relative size of treated tumor groups compared
with that of the untreated tumor control group (T/C), expressed as percentages. Two different erlotinib concentrations were
used for these experiments: 50 mg/kg/d for the erlotinib-resistant models (H1975 xenograft) and 20 mg/kg/d for the
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regimen resulted in higher efﬁcacy (Fig. 6E and F).
Accordingly, the combined treatment more effectively
inhibited FGFR1, EGFR, STAT3, p42/p44, and AKT than
did either drug alone (Fig. 6G).The Expression of FGFR1 Is a Potential
Predictive Biomarker for Anti-EGFR Therapy
Efﬁcacy
FGFR1 mRNA expression was determined in
formalin-ﬁxed parafﬁn-embedded tumor samples from a
cohort of patients with adenocarcinoma (including
EGFR-mutated and EGFR wild-type tumors) treated with
erlotinib or geﬁtinib with no prior anti-EGFR treatment
(n ¼ 47 [see Supplementary Table 2 and Fig. 6H]). We
found that patients with high FGFR1 expression had a
shorter progression-free period than the rest of the
patients did (HR ¼ 4.10, 95% conﬁdence interval: 2.01–
8.33, p < 0.001). In concondance with our previous re-
sults, these observations seemed to be independent of
the presence of EGFR activating mutations, as similar
results were obtained when only the EGFR-mutated or
EGFR wild-type tumors were independently analyzed
(Supplementary Fig. 3A and B). When we repeated these
analyses in an extended cohort including patients with
squamous and other NSCLC histological subtypes (n ¼
87 [see Supplementary Table 2]), we found the
same effects (HR ¼ 3.44, 95% conﬁdence interval: 2.09–
5.67, p < 0.001) for high FGFR1 expression
(Supplementary Fig. 3C). We discarded the idea that
these results were derived from a prognostic role of
FGFR1 after analyzing The Cancer Genome Atlas lung
cancer cohort, the patients of which were not known not
receive an especiﬁc treatment targeting EGFR or FGFR
(Supplementary Fig. 3D).
Discussion
We have shown here that FGFR1 cooperates with
EGFR in EGFR-dependent lung adenocarcinoma through
a reciprocal overactivation. Consistently, tumoral over-
expression of FGFR1 determined decreased sensitivity to
EGFR tyrosine kinase inhibitors in vitro and in vivo and
conferred a poorer prognosis to patients treated with
those inhibitors. Furthermore, we have provided in vitroerlotinib-sensitive model (HCC827 xenograft). Four mice were in
included in the EGFR inhibitor or combination treatment groups
case. (C) Western blots showing the impact of treatment of H
overexpression, on the activation of protumorigenic signaling
different mice were randomly selected In the FGFR1-overexpre
empty vector untreated control (EV) was added for comparison
test and are indicated by asterisks (*p < 0.05, **p < 0.01, and
phorylated signal transducer and activator of transcription 3; ST
phosphorylated AKT.(H1975 and HCC827) and in vivo (HCC827) evidence
that the combination of EGFR and FGFR inhibition may
be an effective therapy in EGFR-activated plus FGFR1-
expressing lung adenocarcinoma tumors.
FGFR1 overexpression in EGFR-mutated models
caused an increase in tumorigenicity in vivo and in vitro,
which was accompanied by activation of EGFR and
downstream signaling. We have also reproduced this
FGFR-EGFR interaction in an immortalized lung cell line,
conﬁrming that the described cooperation is not exclu-
sive to tumors with EGFR harboring activating mutations
but also takes place in cells with overactivated wild-type
EGFR.
EGFR was found to colocalize and coimmunopreci-
pitate with FGFR1, supporting a physical interaction
between these molecules. Interestingly, pEGFR levels
increased after stimulation with FGFR-speciﬁc ligands as
phosphorylation of the FGFRs occurs after stimulation
with EGF, thus providing biochemical evidence for EGFR-
FGFR cooperation. These results are in accordance with
previous data in the literature for another member of the
FGFR family, showing that mouse embryonic ﬁbroblasts
transformed by EGFR overexpression display higher
levels of FGFR4 expression than mouse embryonic
ﬁbroblasts transformed by other means.30 FGFR1 over-
expression in this context may further activate EGFR,
which could confer a selective growth and tumorigenic
advantage.
The EGFR-FGFR1 cooperation suggests a potential
therapeutic opportunity for tumors with EGFR activation
and high expression of these FGFRs. Indeed, we reported
higher efﬁcacy of dual EGFR/FGFR inhibition in EGFR-
dependent models with FGFR1 overexpression in vitro
and in vivo, showing dramatic results in EGFR-mutated
cell line xenograft models overexpressing FGFR1 and
in PDXs with high EGFR activation (one with an EGFR
activating mutation and two with wild-type EGFR).
Remarkably, two of these models, in which the combined
EGFR/FGFR inhibition showed high efﬁcacy, harbored
the erlotinib resistance T790M mutation, which high-
lights the importance of the FGFR1-EGFR cooperation
even in the presence of erlotinib resistance mutations.
However, the high efﬁcacy of this combined therapy in
these two erlotinib-resistant models may be due to the
relatively low duration of the treatments. In any case,cluded in the control and AZD4547 groups, and six mice were
. AZD4547 was administered at a dose of 5 mg/kg/d in every
1975 and HCC827 xenograft models with or without FGFR1
. For the Western blots shown, three tumors coming from
ssing xenograft Western blots, one protein sample from the
. p Values were obtained with the two-sided Mann-Whitney U
***p < 0.001). pEGFR, phosphorylated EGFR; pSTAT3, phos-
AT3, signal transducer and activator of transcription 3; pAKT,
Figure 6. Effect of dual EGFR and ﬁbroblast growth factor receptor inhibition in EGFR-activated ﬁbroblast growth factor
receptor 1 (FGFR1)-expressing lung adenocarcinoma patient-derived xenograft (PDX) models and impact of FGFR1 expression
on response to anti-EGFR treatment. (A) Western blot showing the FGFR1, phosphorylated EGFR (pEGFR) and EGFR protein
levels for the selected PDX models. The Western blot image was cropped and assembled from a broader image including more
lanes. A negative control for pEGFR expression (control) in shown. (B) Effect of erlotinib and AZD4547 on tumor growth of
lung adenocarcinoma PDX models. (C) Median relative size of treated tumor groups compared with that of the untreated
tumor control group (T/C), expressed as percentages. (D) Western blots showing the impact of treatment on this model in the
activation of protumorigenic signaling. (E) Effect of osimertinib and AZD4547 on tumor growth of the lung adenocarcinoma
TP103 PDX model. (F) Median relative size of treated TP103 tumor groups compared with that of the untreated tumor control
group (T/C), expressed as percentages. (G) Western blots showing the impact of osimertinib and AZD4547 treatment on the
activation of protumorigenic signaling in the TP103 PDX model. (H) Effect of FGFR1 mRNA expression on progression-free
survival of patients with erlotinib- or geﬁtinib-treated lung adenocarcinoma (see Supplementary Table 2 for a description
of the cohort). FGFR1 mRNA expression was determined as stated in the Methods section, and beta-2-microglobulin
housekeeping gene (B2M) expression was used to normalize FGFR1 expression across samples. To deﬁne the groups of
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bined inhibition of EGFR and FGFR in EGFR-activated
FGFR1-overexpressing tumors regardless of the pres-
ence of EGFR mutations. It is important to note that
therapeutic regimens using more than one cell-signaling
inhibitor frequently present increased adverse effects,
which hinder their clinical application.31,32 Toxicity
enhancement is typically reported when unselective in-
hibitors that are molecularly promiscuous with
numerous off-target effects are combined.33,34 In this
regard, a recent phase I trial testing the safety of erlo-
tinib combined with the FGFR unselective inhibitor
dovitinib in patients with NSCLC was terminated
because of unacceptable toxicity.35 In the present work,
however, we have proposed combining EGFR inhibitors
with a more selective FGFR1 inhibitor, hoping to result
in a more favorable tolerability proﬁle.
To assess whether the described cooperation be-
tween the EGFR and FGFR receptors was relevant at the
clinical level, we determined the effect on progression-
free survival of FGFR1 expression in patients with
adenocarcinoma who were receiving erlotinib or geﬁti-
nib. As we had observed EGFR-FGFR1 cooperation taking
place not only with mutated EGFR but also with its wild-
type variant, we included wild-type and mutated EGFR
tumors in this analysis and found shorter times to pro-
gression for patients with high FGFR1 expression.
Interestingly, concordant results were obtained from
analysis of an extended cohort in which all NSCLC his-
tologic types were represented, which suggests that
these ﬁndings may be applicable beyond adenocarci-
noma tumors. In line with this, NSCLC cells from all
histologic types with high FGFR1 expression levels and
EGFR activation showed increased resistance to EGFR
inhibitors. Upregulation of some FGFRs, such as FGFR1
or ﬁbroblast growth factor receptor 2, and ﬁbroblast
growth factor receptor 3, mutations have been reported
as mechanisms of acquired resistance to anti-EGFR
therapy,22–24,36,37 and combined EGFR and FGFR inhi-
bition has been proposed in this setting. Furthermore,
ﬁbroblast growth factor receptor 2 inhibition has been
linked to increased erlotinib sensitivity in several in vitro
models of lung cancer.38 These results certainly suggest
a relationship between both EGFR and FGFR receptors inFGFR1-high and FGFR1-low patients, the median normalized F
were included in the control and AZD4547 groups, and six mice w
groups. Two different erlotinib concentrations were used for t
model (TP103) and 20 mg/kg/d for the models with no predic
administered at a dose of 10 mg/kg/d. AZD4547 was administere
shown, three tumors coming from different mice were randoml
the two-sided Mann-Whitney U test and with the log-rank test fo
explicitly stated (*p < 0.05, **p < 0.01, and ***p < 0.001). Low/
phosphorylated ﬁbroblast growth factor receptor 1; pSTAT3, ph
3; STAT3, signal transducer and activator of transcription 3; pAacquired resistance to anti-EGFR inhibition. However, we
are the ﬁrst to report a reciprocal activating interaction
between FGFR1 and EGFR leading to intrinsic anti-EGFR
resistance. Our data provide clinical evidence that tu-
mors may exhibit high levels of FGFR1 expression before
anti-EGFR therapy, which would make EGFR inhibition
less effective: patients bearing tumors with these char-
acteristics may beneﬁt from dual inhibition of EGFR and
FGFR, which would overcome this primary resistance.
Prooncogenic cooperation among receptor tyrosine
kinases, similar to the FGFR1-EGFR interaction reported
here for lung cancer, occurs in diverse malignancies.
Insulin-like growth factor 1 receptor (IGF1R) has been
found to interact with the insulin receptor in gastric and
hepatocellular carcinoma cell lines, and the treatment of
these cell lines with an antibody targeting this interac-
tion reduces STAT3 and AKT activation.39 In bladder
cancer, it has been reported that EGFR can physically
interact with platelet derived growth factor receptor
beta and induce p42/p44 activation and resistance to
anti-EGFR therapy.40
In the context of lung cancer, the heterodimerization
of EGFR with IGF1R has also been described as a
mechanism of erlotinib resistance, which could be
bypassed through IGF1R inhibition.41
EGFR activation induces FGFR1 inhibition resistance
in head and neck carcinoma cell lines, suggesting that the
FGFR1-EGFR interaction may be of relevance in other
tumor types as well.42 To date, most targeted thera-
peutic approaches in the lung cancer setting have
focused on concrete driver genetic alterations, but all of
those data, along with the results of the present work,
highlight the importance of a more comprehensive mo-
lecular characterization of tumors that harbor not just
one but numerous molecular aberrations. The study of
the coactivation of diverse signaling pathways may be of
clinical relevance for predicting primary resistance to
targeted therapies and the identiﬁcation of efﬁcacious
combination therapies.
Thus, determination of the expression levels of
FGFR1 and the activation of EGFR, not only in EGFR-
mutated tumors but also in EGFR wild-type tumors,
may be predictive of efﬁcacy of EGFR inhibition, as well
as of the effectiveness of combination therapy with EGFRGFR1 mRNA expression value was used as cutoff. Four mice
ere included in the EGFR inhibitor or combination treatment
he PDXs experiments: 50 mg/kg/d for the erlotinib-resistant
ted erlotinib sensitivity (TP57 and TP126). Osimertinib was
d at a dose of 5 mg/kg/d in every case. For the Western blots
y selected. p Values for the in vivo assay were obtained with
r the survival analysis and are indicated by asterisks when not
High FGFR1, low or high mRNA expression of FGFR1; pFGFR1,
osphorylated signal transducer and activator of transcription
KT, phosphorylated AKT.
654 Quintanal-Villalonga et al Journal of Thoracic Oncology Vol. 14 No. 4and FGFR inhibitors. Therefore, we have proposed a
highly effective therapeutic tailored approach for a
subset of EGFR-dependent tumors with high FGFR1
expression levels, and we have provided molecular
criteria for the selection of patients who would beneﬁt
from this therapy, thus extending the use of EGFR in-
hibitors to wild-type activated EGFR tumors.
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